Literature DB >> 28344891

Tumor-infiltrating CD39+γδTregs are novel immunosuppressive T cells in human colorectal cancer.

Guoming Hu1, Pin Wu2, Pu Cheng1, Zhigang Zhang3, Zhen Wang1, Xiuyan Yu4, Xuan Shao4, Dang Wu5, Jun Ye6, Tao Zhang7, Xiaochen Wang4, Fuming Qiu1, Jun Yan8, Jian Huang1.   

Abstract

Tumor microenvironment (TME) promotes immune suppression through recruiting and expanding suppressive immune cells such as regulatory T cells (Tregs) to facilitate cancer progression. In this study, we identify a novel CD39+ γδTreg in human colorectal cancer (CRC). CD39+ γδTregs are the predominant regulatory T cells and have more potent immunosuppressive activity than CD4+ or CD8+ Tregs via the adenosine-mediated pathway but independent of TGF-β or IL-10. They also secrete cytokines including IL-17A and GM-CSF, which may chemoattract myeloid-derived suppressive cells (MDSCs), thus establishing an immunosuppressive network. We further demonstrate that tumor-derived TGF-β1 induces CD39+ γδT cells from paired normal colon tissues to produce more adenosine and become potent immunosuppressive T cells. Moreover, CD39+ γδTreg infiltration is positively correlated with TNM stage and other unfavorable clinicopathological features, implicating that CD39+ γδTregs are one of the key players in establishment of immunosuppressive TME in human CRC that may be critical for tumor immunotherapy.

Entities:  

Keywords:  Adenosine; CD39+ γδTregs; human CRC; tumor-derived TGF-β1

Year:  2017        PMID: 28344891      PMCID: PMC5353931          DOI: 10.1080/2162402X.2016.1277305

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  51 in total

1.  Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells.

Authors:  Xunrong Luo; Kristin V Tarbell; Hua Yang; Kathryn Pothoven; Samantha L Bailey; Ruchuang Ding; Ralph M Steinman; Manikkam Suthanthiran
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-16       Impact factor: 11.205

2.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

3.  CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells.

Authors:  Mardi C Boer; Krista E van Meijgaarden; Jérémy Bastid; Tom H M Ottenhoff; Simone A Joosten
Journal:  Eur J Immunol       Date:  2013-05-29       Impact factor: 5.532

4.  Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations.

Authors:  Q Zhou; J Yan; P Putheti; Y Wu; X Sun; V Toxavidis; J Tigges; N Kassam; K Enjyoji; S C Robson; T B Strom; W Gao
Journal:  Am J Transplant       Date:  2009-07-28       Impact factor: 8.086

Review 5.  Beyond ecto-nucleotidase: CD39 defines human Th17 cells with CD161.

Authors:  Aiping Bai; Simon Robson
Journal:  Purinergic Signal       Date:  2015-06-10       Impact factor: 3.765

6.  Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway.

Authors:  Guangyong Peng; Helen Y Wang; Weiyi Peng; Yukiko Kiniwa; Kook Heon Seo; Rong-Fu Wang
Journal:  Immunity       Date:  2007-07-26       Impact factor: 31.745

7.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

8.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Authors:  François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre E Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

9.  CD39 Expression Identifies Terminally Exhausted CD8+ T Cells.

Authors:  Prakash K Gupta; Jernej Godec; David Wolski; Emily Adland; Kathleen Yates; Kristen E Pauken; Cormac Cosgrove; Carola Ledderose; Wolfgang G Junger; Simon C Robson; E John Wherry; Galit Alter; Philip J R Goulder; Paul Klenerman; Arlene H Sharpe; Georg M Lauer; W Nicholas Haining
Journal:  PLoS Pathog       Date:  2015-10-20       Impact factor: 6.823

10.  NADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine.

Authors:  Aiping Bai; Alan Moss; Sonja Rothweiler; Maria Serena Longhi; Yan Wu; Wolfgang G Junger; Simon C Robson
Journal:  Nat Commun       Date:  2015-11-09       Impact factor: 14.919

View more
  29 in total

Review 1.  Regulatory functions of γδ T cells.

Authors:  Christian Peters; Dieter Kabelitz; Daniela Wesch
Journal:  Cell Mol Life Sci       Date:  2018-03-08       Impact factor: 9.261

2.  IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population.

Authors:  Clément Barjon; Henri-Alexandre Michaud; Angeline Fages; Cécile Dejou; Alexandre Zampieri; Laetitia They; Aurélie Gennetier; Françoise Sanchez; Laurent Gros; Jean-François Eliaou; Nathalie Bonnefoy; Virginie Lafont
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 3.  γδ T Cells: Unexpected Regulators of Cancer Development and Progression.

Authors:  Christopher Fleming; Samantha Morrissey; Yihua Cai; Jun Yan
Journal:  Trends Cancer       Date:  2017-07-17

4.  PD-1 signaling modulates interferon-γ production by Gamma Delta (γδ) T-Cells in response to leukemia.

Authors:  Timm Hoeres; Elisabeth Holzmann; Manfred Smetak; Josef Birkmann; Martin Wilhelm
Journal:  Oncoimmunology       Date:  2018-12-14       Impact factor: 8.110

Review 5.  Targeting Cytokine Signals to Enhance γδT Cell-Based Cancer Immunotherapy.

Authors:  Yuan Song; Yonghao Liu; Huey Yee Teo; Haiyan Liu
Journal:  Front Immunol       Date:  2022-06-07       Impact factor: 8.786

Review 6.  Tregs: Where We Are and What Comes Next?

Authors:  Hai Zhao; Xuelian Liao; Yan Kang
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

Review 7.  What Else Can CD39 Tell Us?

Authors:  Hai Zhao; Cong Bo; Yan Kang; Hong Li
Journal:  Front Immunol       Date:  2017-06-22       Impact factor: 7.561

8.  Aberrant Peripheral Immune Function in a Good Syndrome Patient.

Authors:  Xian Chen; Jie-Xin Zhang; Wen-Wen Shang; Wei-Ping Xie; Shu-Xian Jin; Fang Wang
Journal:  J Immunol Res       Date:  2018-04-23       Impact factor: 4.818

9.  Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells.

Authors:  Chao Ni; Qing-Qing Fang; Wu-Zhen Chen; Jin-Xing Jiang; Zhou Jiang; Jun Ye; Ting Zhang; Liu Yang; Fan-Bo Meng; Wen-Jie Xia; Miaochun Zhong; Jian Huang
Journal:  Signal Transduct Target Ther       Date:  2020-04-29

Review 10.  γδ T Cells: Crosstalk Between Microbiota, Chronic Inflammation, and Colorectal Cancer.

Authors:  Yunben Yang; Chunjing Xu; Dang Wu; Zhen Wang; Pin Wu; Lili Li; Jian Huang; Fuming Qiu
Journal:  Front Immunol       Date:  2018-06-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.